<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480451</url>
  </required_header>
  <id_info>
    <org_study_id>28280</org_study_id>
    <nct_id>NCT03480451</nct_id>
  </id_info>
  <brief_title>Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>IPF</acronym>
  <official_title>Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF), a chronic fibrotic lung disease of unknown cause, is
      characterized by relentless progression, with a three-year mortality of up to 50%. IPF has
      high morbidity, with 90% of patients reporting dyspnea at the time of diagnosis and this is
      strongly correlated with quality of life and mortality. As IPF progress, breathlessness
      worsens, physical functional capacity declines, and health-related quality of life
      deteriorates. Pulmonary rehabilitation (PR) can improve well-being in patients with other
      chronic lung disease, but little is known regarding PR in IPF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis is that the provision of a comprehensive pulmonary rehabilitation program to
      patients with IPF will significantly improve participant health related quality of life. The
      objective is to develop a comprehensive, multi-disciplinary 12-week PR program with disease
      specific educational components for IPF patients. The specific aims of the proposal is to
      evaluate the effect of the comprehensive PR program on 1) improvements in quality of life
      using the Medical Outcomes Study 36-Item Short Form 36 (SF-36), a quality of life instrument
      and 2) improvements in patient self-reported dyspnea scores using the chronic respiratory
      questionnaire. The investigator intends to evaluate sustained benefits of the PR
      intervention, changes in depression, anxiety, stress and functional physical capacity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the change in coping skills for patients with IPF before and after a comprehensive pulmonary rehabilitation program.</measure>
    <time_frame>12 months</time_frame>
    <description>Will use COPE questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the change in quality of life for patients with IPF before and after a comprehensive pulmonary rehabilitation program.</measure>
    <time_frame>12 months</time_frame>
    <description>Will use 36-item SF questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the change in depression, anxiety for patients with IPF before and after a comprehensive pulmonary rehabilitation program.</measure>
    <time_frame>12 months</time_frame>
    <description>Will use DASS-21 questionnaire.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multi-Disciplinary Patient Centered Rehab and Education</intervention_name>
    <description>Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IPF confirmed by lung biopsy or by characteristic pattern on high
             resolution computed tomogram (HRCT)

          -  No identifiable cause of lung fibrosis

          -  PR not received in the past year

          -  Ability to walk

        Exclusion Criteria:

          -  History of unstable angina

          -  Deterioration cardiac or neurological disease

          -  Pregnancy or lactation

          -  Degenerative arthritis or other limitation to mobility

          -  PR in the past 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Ramalingam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of WI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanette Graf, BS, CCRP</last_name>
    <phone>414-955-7040</phone>
    <email>jgraf@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Zellner, MS, CCRC</last_name>
    <phone>414-955-7040</phone>
    <email>szellner@mcw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Ramalingam, MD</last_name>
      <phone>414-955-7040</phone>
    </contact>
    <contact_backup>
      <last_name>Jeanette Graf, CCRP</last_name>
      <phone>414-955-6987</phone>
      <email>lung@mcw.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.</citation>
    <PMID>21471066</PMID>
  </reference>
  <reference>
    <citation>Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008 Mar 26;3:8. doi: 10.1186/1750-1172-3-8. Review.</citation>
    <PMID>18366757</PMID>
  </reference>
  <reference>
    <citation>Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998 Jan;157(1):199-203.</citation>
    <PMID>9445300</PMID>
  </reference>
  <reference>
    <citation>Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005 Jul;60(7):588-94. Review.</citation>
    <PMID>15994268</PMID>
  </reference>
  <reference>
    <citation>Olson AL, Brown KK, Swigris JJ. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas. 2016 May 17;7:29-35. doi: 10.2147/PROM.S74857. eCollection 2016. Review.</citation>
    <PMID>27274328</PMID>
  </reference>
  <reference>
    <citation>Belkin A, Swigris JJ. Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med. 2013 Sep;19(5):474-9. doi: 10.1097/MCP.0b013e328363f479. Review.</citation>
    <PMID>23851327</PMID>
  </reference>
  <reference>
    <citation>Morisset J, Dubé BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, Lee JS. The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation. Ann Am Thorac Soc. 2016 Jul;13(7):1026-33. doi: 10.1513/AnnalsATS.201512-836OC.</citation>
    <PMID>27064659</PMID>
  </reference>
  <reference>
    <citation>Lacasse Y, Martin S, Lasserson TJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A Cochrane systematic review. Eura Medicophys. 2007 Dec;43(4):475-85. Review.</citation>
    <PMID>18084170</PMID>
  </reference>
  <reference>
    <citation>Nici L, ZuWallack R; American Thoracic Society Subcommittee on Integrated Care of the COPD Patient. An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proc Am Thorac Soc. 2012 Mar;9(1):9-18. doi: 10.1513/pats.201201-014ST.</citation>
    <PMID>22421582</PMID>
  </reference>
  <reference>
    <citation>Harrison SL, Greening NJ, Williams JE, Morgan MD, Steiner MC, Singh SJ. Have we underestimated the efficacy of pulmonary rehabilitation in improving mood? Respir Med. 2012 Jun;106(6):838-44. doi: 10.1016/j.rmed.2011.12.003. Epub 2011 Dec 23.</citation>
    <PMID>22197576</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Vijaya Ramalingam</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

